Glenmark launches Calcium Gluconate Injection in $69.9m US market

0 min read | Published on 21 Aug 2026, 08:59 AM |Updated on 21 Aug 2026, 09:02 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Glenmark launches Calcium Gluconate Injection USP in the US
Targets a $69.9 million annual market segment
Product is bioequivalent to Fresenius Kabi's reference drug
Offers three strength configurations for hospital use

*this image is generated using AI for illustrative purposes only.

Glenmark Pharmaceuticals has launched Calcium Gluconate Injection USP in the United States, targeting a significant segment of the hospital injectables market. The launch includes single-dose vials and pharmacy bulk packages in three strength configurations.

The new product is bioequivalent and therapeutically equivalent to the reference listed drug manufactured by Fresenius Kabi USA, LLC. Glenmark’s offering covers 1,000 mg/10 mL, 5,000 mg/50 mL, and 10,000 mg/100 mL formulations.

Market Opportunity

According to IQVIA sales data for the 12-month period ending June 2026, the relevant market for these injection strengths achieved annual sales of approximately $69.9 million. This figure encompasses both brand products and all available therapeutic equivalents.

Strategic Expansion

Marc Kikuchi, President & Business Head for North America, stated that the launch strengthens Glenmark’s U.S. injectables business. He noted the move expands the hospital portfolio and supports supply resilience across the U.S. healthcare system.

What the Numbers Show

The entry into a nearly $70 million market with a therapeutically equivalent generic suggests a direct competitive challenge to Fresenius Kabi. By offering multiple package sizes including pharmacy bulk packages, Glenmark aims to capture institutional demand where volume pricing often drives procurement decisions.

Historical Stock Returns for Glenmark Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.58%	-0.03%	+3.56%	+13.51%	+20.55%	+329.70%

How might Fresenius Kabi adjust its pricing or supply chain strategy to defend its market share against Glenmark's new generic entry?

What impact could this launch have on Glenmark's overall revenue contribution from the U.S. hospital injectables segment in the next fiscal year?

Are there potential regulatory or supply chain risks associated with the production of high-volume Calcium Gluconate injections that Glenmark must mitigate?

Glenmark Pharmaceuticals

View Company Insights

View All News

Glenmark Pharma secures US FDA nod for Fluticasone Nasal Spray

1 min read | Published on 20 Aug 2026, 09:00 AM |Updated on 20 Aug 2026, 09:01 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Glenmark Pharmaceuticals received US FDA approval on August 20, 2026, for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray, bioequivalent to Flonase® Nasal Spray by Haleon US Holdings LLC [NDA 020121]. The addressable market for the reference drug stood at approximately $295.2 million in annual sales for the 12 months ending June 2026, per IQVIA® data. Glenmark Pharmaceuticals Inc., USA will distribute the product in the US market.

*this image is generated using AI for illustrative purposes only.

Glenmark Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for its Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The company announced the regulatory milestone on August 20, 2026, marking an expansion of its respiratory portfolio in the United States.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase® Nasal Spray, 0.05 mg/spray, manufactured by Haleon US Holdings LLC [NDA 020121]. Glenmark Pharmaceuticals Inc., USA will handle the distribution of the nasal spray in the US market. The FDA approval is limited to the indications listed in Glenmark's approved label, which may differ from the approved indications of the reference listed drug.

Market context

According to IQVIA® sales data for the 12 months ending June 2026, the total market for Flonase® Nasal Spray, including brand and all available therapeutic equivalents, achieved annual sales of approximately $295.2 million. The table below summarises the key details of the approved product.

Parameter:	Details
Product:	Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray
Reference drug:	Flonase® Nasal Spray, 0.05 mg/spray
Reference NDA:	NDA 020121
Manufacturer of reference drug:	Haleon US Holdings LLC
US distributor:	Glenmark Pharmaceuticals Inc., USA
Addressable market (annual):	$295.2 million
Market data period:	12 months ending June 2026
Market data source:	IQVIA®

What the numbers show

With the reference drug commanding approximately $295.2 million in annual sales, Glenmark's entry targets a well-established segment within respiratory care. The approval positions the company to compete through price competitiveness, a standard dynamic in the generic pharmaceuticals sector.

Executive commentary

Marc Kikuchi, President and Business Head for North America at Glenmark, stated that the approval builds on the strong foundation the company has established in the respiratory therapeutic area. He emphasised the company's commitment to broadening access to quality, affordable treatment options for patients and healthcare providers.

Historical Stock Returns for Glenmark Pharmaceuticals

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.58%	-0.03%	+3.56%	+13.51%	+20.55%	+329.70%

How might Glenmark's pricing strategy for this generic Fluticasone Propionate Nasal Spray impact Haleon's market share in the $295.2 million addressable market?

What is the expected timeline for Glenmark to achieve significant sales volume given the existing competition from other therapeutic equivalents?

How does this approval align with Glenmark's broader pipeline strategy for expanding its respiratory portfolio in the US over the next 12 to 24 months?

Glenmark Pharmaceuticals

View Company Insights

View All News